Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

935
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
935
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

798
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
798
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

421
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
421
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

150
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
150

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vericiguat therapy reduces arrhythmic events in heart failure patients with cardiac implantable electronic devices.

Heart rhythm·2026
Same author

Multi-Chamber Reverse Remodeling and Hemodynamic Force Realignment After SGLT2 Inhibitor Initiation in Real-World Heart Failure.

Journal of cardiovascular development and disease·2026
Same author

Incidence of Migraine Following Pulsed-Field Ablation for Atrial Fibrillation: Findings From a Multicenter Analysis.

Journal of cardiovascular electrophysiology·2026
Same author

Tricuspid Regurgitation: Pathophysiology, Risk Stratification, and Implications for Intervention.

Journal of clinical medicine·2026
Same author

An Assessment of the Paediatric Cardiovascular Risk Profile in San Nicola da Crissa, a Village in the Calabria Region (Southern Italy): A Cross-Sectional Study.

Journal of cardiovascular development and disease·2026
Same author

A Clinician-Oriented Approach to Plaque Pathology in ACS: Implications for Personalized Cardiovascular Medicine-A Comprehensive Review.

Journal of personalized medicine·2026

Related Experiment Video

Updated: Jun 15, 2025

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K

Antiarrhythmic Drug Use in Pregnancy: Considerations and Safety Profiles.

Marco Valerio Mariani1, Nicola Pierucci1,2, Vincenzo Mirco La Fazia2

  • 1Department of Clinical Internal Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.

Journal of Cardiovascular Development and Disease
|August 28, 2024
PubMed
Summary

Pregnancy-related arrhythmias require careful management due to potential risks to mother and fetus. Antiarrhythmic drug (AAD) use during pregnancy necessitates individualized treatment and close monitoring for optimal outcomes.

Keywords:
antiarrhythmic drugsarrhythmiapregnancy

More Related Videos

Noninvasive Electrocardiography in the Perinatal Mouse
04:36

Noninvasive Electrocardiography in the Perinatal Mouse

Published on: June 12, 2020

6.0K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.0K

Related Experiment Videos

Last Updated: Jun 15, 2025

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K
Noninvasive Electrocardiography in the Perinatal Mouse
04:36

Noninvasive Electrocardiography in the Perinatal Mouse

Published on: June 12, 2020

6.0K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.0K

Area of Science:

  • Cardiology
  • Maternal-Fetal Medicine
  • Pharmacology

Background:

  • Pregnancy involves significant physiological and hormonal changes impacting maternal and fetal health.
  • Cardiovascular events, particularly arrhythmias, pose serious risks during pregnancy, especially for those with pre-existing conditions.
  • Understanding the nuances of arrhythmias in pregnancy is crucial for effective management.

Purpose of the Study:

  • To provide a comprehensive overview of arrhythmia prevalence, treatment options, and prognoses in pregnant individuals.
  • To discuss the safety profiles and potential risks associated with antiarrhythmic drug (AAD) administration during pregnancy.
  • To emphasize the importance of personalized treatment strategies and vigilant monitoring for pregnant women with arrhythmias.

Main Methods:

  • Literature review on the epidemiology of arrhythmias in pregnancy.
  • Analysis of current therapeutic approaches for managing arrhythmias during gestation.
  • Evaluation of the safety data and potential adverse effects of various antiarrhythmic drug classes in pregnant populations.

Main Results:

  • Arrhythmias during pregnancy present unique challenges due to physiological adaptations and potential drug-related risks.
  • Antiarrhythmic drugs (AADs) can cross the placenta and enter breast milk, potentially causing teratogenicity, growth restriction, or premature birth.
  • Different classes of AADs exhibit varying safety profiles, requiring careful selection based on individual patient factors.

Conclusions:

  • Individualized treatment plans are essential for managing arrhythmias in pregnant women.
  • Close maternal and fetal monitoring is critical when antiarrhythmic drugs are prescribed during pregnancy.
  • Optimizing maternal and fetal outcomes requires a thorough understanding of arrhythmia management in the context of pregnancy.